Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-16-Speech-3-206-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2011-02-16"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20110216.11.3-206-000"2
lpv:hasSubsequent	lp_eu:2011-02-16-Speech-3-207-0002
lpv:speaker	lp:Anne Delvaux2
lpv:spokenAs	member; EPP (2009-07-14--2014-06-30)3 substitute; FEMM (2010-08-30--2012-01-18)3 substitute; Delegation for relations with South Africa (2009-09-16--2014-06-30)3 member; ENVI (2009-07-16--2012-01-18)3 member; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2014-06-30)3 unknown; Centre Démocrate Humaniste (2009-07-14--2014-06-30)3 member; Delegation for relations with the Pan-African Parliament (2009-09-16--2014-06-30)3 substitute; LIBE (2009-07-16--2012-01-18)3
lpv:translated text	"I voted in favour of this report, as it aims to combat at EU level falsified medicines within the legal supply chain without hampering the functioning of the internal market in medicines. It aims to do so, for example, by introducing obligations for operators in the distribution chain, by prohibiting those operators situated between the original manufacturer and the final operator in the distribution chain (generally the pharmacist) or the end user (doctor/patient) from manipulating (that is removing, modifying or covering) the safety features on the packaging, and by establishing stricter criteria governing the importation of active pharmaceutical ingredients from third countries and product inspections."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph